Skip To Main Content
Darpan Singh on Muck Rack

Darpan Singh

  • Assistant Editor, Times of India - New Delhi Edition, The
National Capital Territory of Delhi, New Delhi
As seen in: Daily Mail, MSN India, India Today, DNA India, DailyO, IP Watchdog, Mondaq, Westlaw Today, Ex Bulletin, Intellectual Asset Management and
Journalist | Former Executive Editor @IndiaToday | Previously: ToI, HT, Asian Age, DNA, etc
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Darpan

Contact Darpan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Axinn Associates At The Antitrust Spring Meeting: Tech-Related Enforcement

|
By Laviana Alharmoosh, Maryanne Magnier, Darpan Singh
| Mondaq
AV Axinn Veltrop & Harkrider More Incisive. Inclusive. Invested. We’re Axinn. Experienced, tenacious, and always trial-ready, we are committed to understanding complex legal challenges that impact the future of our clients’ businesses, globally. Focusing on antitrust, intellectual property, and high-stakes litigation, our extensive teams in the U.S. possess deep knowledge and client-side experience across a range of sectors, including technology, healthcare, life sciences, and consumer products.
Open in Who Shared Issue with article?

Patent eligibility in the AI era: aligning judicial precedent with USPTO guidance

|
By Brian Johnson, Joseph A Micallef, Darpan Singh
| Intellectual Asset Management Verified
Shutterstock/Who is Danny The divergent interpretations of patent eligibility between the USPTO and the Federal Circuit, especially for AI patents, raise questions about their vulnerability to post-grant challenges Register for limited access Register to receive our newsletter and gain limited access to subscriber content. Register now Subscribe to unlock unlimited access Get news, unique commentary, expert analysis and essential resources from the IAM experts. Subscribe now Already have access?
Open in Who Shared Issue with article?

The US FTC renews pressure on pharmaceutical companies over allegedly improper device patent listings delaying generic competition – Concurrences

|
By Matthew Becker, Ross Blau, Neelesh Moorthy, Darpan Singh
| Concurrences Verified
Previous article Next article Share on | The Federal Trade Commission (FTC) is continuing to pursue pharmaceutical manufacturers for allegedly improperly listing patents in the “Orange Book,” delaying the entry of generic drug competitors.
Open in Who Shared Issue with article?
See all 180 licensed articles (245 Total)